Developing therapeutic proteins by engineering ligand-receptor interactions.
Ligand-receptor interactions govern myriad cell signaling pathways that regulate homeostasis and ensure that cells respond properly to stimuli. Growth factors, cytokines and other regulatory elements use these interactions to mediate cell responses, including proliferation, migration, angiogenesis, immune responses and cell death. Proteins that inhibit these processes have potential as therapeutics for cancer and autoimmune disorders, whereas proteins that stimulate these processes offer promise in regenerative medicine. Although much of the focus in this area over the past decade has been on monoclonal antibodies, recently there has been increased interest in the use of non-antibody proteins as therapeutic agents. Here, we review recent advances and accomplishments in the use of rational and combinatorial protein engineering approaches to developing ligands and receptors as agonists and antagonists against clinically important targets.
Jones
Douglas S
DS
Department of Bioengineering, Stanford University, Stanford, CA 94305, USA.
Silverman
Adam P
AP
Cochran
Jennifer R
JR
D000818:Animals; D001688:Biological Products / Q000627:therapeutic use; D006801:Humans; D008024:Ligands; D011485:Protein Binding / Q000235:genetics; D015202:Protein Engineering / Q000639:trends*; D011506:Proteins / Q000819:agonists* / Q000037:antagonists & inhibitors*; D015398:Signal Transduction / Q000502:physiology
D001688:Biological Products; D008024:Ligands; D011506:Proteins